ARTICLE | Clinical News
Controlled release nitazoxanide: Phase I data
February 23, 2009 8:00 AM UTC
In the double-blind, crossover Phase I OPTIMA HCN-1 trial in 12 healthy volunteers, twice-daily 675 and 1,350 mg controlled release nitazoxanide produced trough plasma concentrations of tizoxanide, th...